| ID | 118989 |
| 著者 |
板東, 浩
Tokushima University|Medical Research|Integrative Medicine Japan, Shikoku Island division
KAKEN研究者をさがす
|
| キーワード | Glucagon-like peptide-1 (GLP-1)
Glucose-dependent insulinotropic polypeptide (GIP)
Dual GIP and GLP-1 receptor agonist
Tirzepatide
SURPASS clinical trials
Four-component major adverse cardiovascular event (MACE-4)
|
| 資料タイプ |
学術雑誌論文
|
| 抄録 | Treatment for Type 2 Diabetes (T2D) includes incretin hormones, such as glucagon-like peptide-1 (GLP-1) and also glucose-dependent insulinotropic polypeptide (GIP). As latest agent for T2D, twincretin of dual GIP and GLP-1 receptor agonist, tirzepatide has been studied for SURPASS clinical trials. Clinical efficacy of tirzepatide (5, 10, 15mg) has been reported, where HbA1c reduction showed 2.01%, 2.24% and 2.30%, respectively and weight reduction of tirzepatide was larger than semaglutide as 1.9kg, 3.6kg and 5.5kg, respectively. For comparative study of four-component major adverse cardiovascular event (MACE-4), tirzepatide showed Hazard Ratios (HRs) of 0.80 for MACE-4 and 0.90 for cardiovascular death.
|
| 掲載誌名 |
Journal of Medical and Clinical Studies
|
| ISSN | 25820869
|
| 出版者 | Pubtexto Publishers
|
| 巻 | 5
|
| 号 | 1
|
| 開始ページ | 169
|
| 発行日 | 2022-07-10
|
| 権利情報 | © 2022 Bando H. this is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
|
| 出版社版DOI | |
| 出版社版URL | |
| フルテキストファイル | |
| 言語 |
eng
|
| 著者版フラグ |
出版社版
|
| 部局 |
医学系
|
